← The Clorox overview

The Clorox vs Kimberly-Clark: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

The Clorox Company (CLX)

Q3 2026
▼2▲1

Clorox's weak core profit and soft demand overshadow GOJO-driven sales growth

  • Fiscal 2026 profit slump Clorox's fiscal 2026 revenue fell 5.4% and earnings per share dropped 26%, with gross margin down 290 basis points on higher manufacturing and logistics costs. This weak profit picture weighs on the stock because it shows the company's core business is struggling.

    It is the latest hard evidence of the company's weak underlying profitability, directly pressuring the stock.

  • Soft consumer demand and inflation Management warned that inflation and value-seeking shoppers will challenge fiscal 2027, offsetting cost savings. Persistent cost inflation and soft demand could keep profits under pressure and limit the company's ability to invest in growth.

    It explains the ongoing demand and cost headwinds that are a key reason the stock is under pressure.

  • GOJO acquisition boosts sales Clorox expects its GOJO acquisition, maker of Purell, to add about 9.5 percentage points to fiscal 2027 sales growth and be accretive to earnings. This deal is a major reason revenue is projected to rise 13-14%, giving the stock a growth catalyst.

    It is the main positive force behind the sales growth outlook and a key support for the stock.

  • Earnings beat but guidance miss Clorox's Q2 revenue and earnings beat estimates, but its fiscal 2027 earnings guidance slightly missed expectations. The beat shows some resilience, but the soft outlook and concerns about muted category growth and market share keep a lid on the stock.

    It captures the mixed near-term signals that are driving investor sentiment and the stock's recent moves.

August 2026
▼2▲1

Clorox's weak core profit and soft demand overshadow GOJO-driven sales growth

  • Fiscal 2026 profit slump Clorox's fiscal 2026 revenue fell 5.4% and earnings per share dropped 26%, with gross margin down 290 basis points on higher manufacturing and logistics costs. This weak profit picture weighs on the stock because it shows the company's core business is struggling.

    It is the latest hard evidence of the company's weak underlying profitability, directly pressuring the stock.

  • Soft consumer demand and inflation Management warned that inflation and value-seeking shoppers will challenge fiscal 2027, offsetting cost savings. Persistent cost inflation and soft demand could keep profits under pressure and limit the company's ability to invest in growth.

    It explains the ongoing demand and cost headwinds that are a key reason the stock is under pressure.

  • GOJO acquisition boosts sales Clorox expects its GOJO acquisition, maker of Purell, to add about 9.5 percentage points to fiscal 2027 sales growth and be accretive to earnings. This deal is a major reason revenue is projected to rise 13-14%, giving the stock a growth catalyst.

    It is the main positive force behind the sales growth outlook and a key support for the stock.

  • Earnings beat but guidance miss Clorox's Q2 revenue and earnings beat estimates, but its fiscal 2027 earnings guidance slightly missed expectations. The beat shows some resilience, but the soft outlook and concerns about muted category growth and market share keep a lid on the stock.

    It captures the mixed near-term signals that are driving investor sentiment and the stock's recent moves.

Latest
▼2▲1

Clorox's weak core profit and soft demand overshadow GOJO-driven sales growth

  • Fiscal 2026 profit slump Clorox's fiscal 2026 revenue fell 5.4% and earnings per share dropped 26%, with gross margin down 290 basis points on higher manufacturing and logistics costs. This weak profit picture weighs on the stock because it shows the company's core business is struggling.

    It is the latest hard evidence of the company's weak underlying profitability, directly pressuring the stock.

  • Soft consumer demand and inflation Management warned that inflation and value-seeking shoppers will challenge fiscal 2027, offsetting cost savings. Persistent cost inflation and soft demand could keep profits under pressure and limit the company's ability to invest in growth.

    It explains the ongoing demand and cost headwinds that are a key reason the stock is under pressure.

  • GOJO acquisition boosts sales Clorox expects its GOJO acquisition, maker of Purell, to add about 9.5 percentage points to fiscal 2027 sales growth and be accretive to earnings. This deal is a major reason revenue is projected to rise 13-14%, giving the stock a growth catalyst.

    It is the main positive force behind the sales growth outlook and a key support for the stock.

  • Earnings beat but guidance miss Clorox's Q2 revenue and earnings beat estimates, but its fiscal 2027 earnings guidance slightly missed expectations. The beat shows some resilience, but the soft outlook and concerns about muted category growth and market share keep a lid on the stock.

    It captures the mixed near-term signals that are driving investor sentiment and the stock's recent moves.

Kimberly-Clark Corporation (KMB)

Q3 2026
▲2▼2

Kimberly-Clark's Kenvue bet meets China and cost setbacks

  • Kenvue acquisition adds major brands Kimberly-Clark agreed to buy Kenvue for $48.7 billion, adding Tylenol and Listerine. The deal is expected to create cost savings and more sales, expanding the company's consumer health business.

    This is the biggest new event of the quarter and a key positive driver.

  • Defensive appeal and dividend strength Kimberly-Clark's everyday products, 4.7% dividend yield, and 54-year record of raising dividends attract income investors. The stock also trades below its usual valuation, offering a margin of safety.

    This explains why investors might still favor the stock despite risks.

  • Regulatory and integration risks for Kenvue deal The Kenvue deal faces reviews in China and the EU that could delay or change it. Integrating Kenvue also brings execution challenges, and Kenvue itself struggles with inflation and tariffs pressuring its profit margins.

    These are major new risks that could hurt the deal's success and KMB's stock.

  • Outlook cut on China allegations and cost pressures Kimberly-Clark lowered its 2026 outlook after China diaper-quality claims and weaker revenue. A distribution-center fire, Middle East conflict, and higher oil prices are adding costs, weighing on results.

    This directly explains the negative revision and operational headwinds this quarter.

August 2026
▼1

Kenvue deal advances but regulatory and earnings risks weigh on KMB

  • Q2 earnings beat but 2026 outlook cut on China allegations Kimberly-Clark beat profit expectations but missed revenue and lowered its full-year outlook, citing profit pressure from false diaper quality allegations in China. The stock trades below analyst targets, and the lowered guidance signals weaker near-term earnings, which pushes the price down.

    This is the core earnings event of the period and directly explains why KMB is under pressure.

  • China antitrust review deepens, adding delay risk to Kenvue deal China's market regulator moved the $49 billion Kenvue acquisition into a phase 2 review, which could delay or change the deal. Even though shares rose slightly that day, a longer review creates uncertainty about whether the deal closes on time and on the expected terms.

    This is a new regulatory hurdle that could affect the deal's timing and value, a key driver for KMB.

  • EU approval sought for Kenvue deal, another regulatory step Kimberly-Clark asked the European Union for permission to buy Kenvue, moving the deal into another review stage. The EU filing is a request, not an approval, so the outcome and any conditions remain uncertain, keeping a cloud over the deal's completion.

    This is a new regulatory development that adds to the deal's uncertainty and is not yet in earlier reports.

  • Kenvue deal nears close but integration and financial risks remain The Kenvue combination has cleared shareholder and U.S. antitrust hurdles and is expected to close in Q4 2026, but Kenvue's recent results showed margin pressure from inflation and tariffs, and the deal still faces foreign approvals and execution risk. The benefits may not be fully realized, which could limit upside for KMB.

    This summarizes the latest status and risks of the deal, a major factor for KMB's future earnings and stock price.

Latest
▼1

Kenvue deal advances but regulatory and earnings risks weigh on KMB

  • Q2 earnings beat but 2026 outlook cut on China allegations Kimberly-Clark beat profit expectations but missed revenue and lowered its full-year outlook, citing profit pressure from false diaper quality allegations in China. The stock trades below analyst targets, and the lowered guidance signals weaker near-term earnings, which pushes the price down.

    This is the core earnings event of the period and directly explains why KMB is under pressure.

  • China antitrust review deepens, adding delay risk to Kenvue deal China's market regulator moved the $49 billion Kenvue acquisition into a phase 2 review, which could delay or change the deal. Even though shares rose slightly that day, a longer review creates uncertainty about whether the deal closes on time and on the expected terms.

    This is a new regulatory hurdle that could affect the deal's timing and value, a key driver for KMB.

  • EU approval sought for Kenvue deal, another regulatory step Kimberly-Clark asked the European Union for permission to buy Kenvue, moving the deal into another review stage. The EU filing is a request, not an approval, so the outcome and any conditions remain uncertain, keeping a cloud over the deal's completion.

    This is a new regulatory development that adds to the deal's uncertainty and is not yet in earlier reports.

  • Kenvue deal nears close but integration and financial risks remain The Kenvue combination has cleared shareholder and U.S. antitrust hurdles and is expected to close in Q4 2026, but Kenvue's recent results showed margin pressure from inflation and tariffs, and the deal still faces foreign approvals and execution risk. The benefits may not be fully realized, which could limit upside for KMB.

    This summarizes the latest status and risks of the deal, a major factor for KMB's future earnings and stock price.

July 2026
▲3▼1

Kimberly-Clark's $48.7B Kenvue Deal and Defensive Strength Drive Upside

  • Kenvue acquisition to create high-margin powerhouse Kimberly-Clark is acquiring Kenvue for $48.7 billion, adding brands like Tylenol and Listerine. The deal is expected to deliver $1.9–2.1 billion in cost synergies and $500 million in profit from revenue synergies within a few years. This expands KMB's portfolio and boosts long-term earnings power.

    The Kenvue deal is the biggest strategic move and directly affects KMB's future growth and profitability.

  • Defensive business and dividend appeal Kimberly-Clark's recession-resistant brands like Huggies and Kleenex provide steady demand. The stock offers a 4.7% dividend yield and has raised dividends for 54 straight years. It trades at about 14 times earnings, below its historical average, making it attractive to income and value investors.

    This explains why investors are willing to pay up for KMB despite market volatility.

  • Arbex joint venture sharpens focus on higher-margin products Kimberly-Clark formed a joint venture called Arbex with Suzano, offloading its lower-margin paper-towel and tissue business. This frees up resources to integrate Kenvue and focus on higher-margin personal-care products, potentially improving overall profitability.

    This strategic move supports margin expansion and the Kenvue integration.

  • Integration and cost risks could weigh on results The Kenvue deal brings execution and integration risks. Also, a California distribution center fire and Middle East conflict inflation are expected to cut second-quarter revenue by $20 million and earnings by $50 million. If oil averages $100 per barrel, additional input costs of $150–170 million could hit the second half.

    These are real near-term headwinds that could pressure KMB's stock if they worsen.

▲3▼1

Kimberly-Clark's $48.7B Kenvue Deal and Defensive Strength Drive Upside

  • Kenvue acquisition to create high-margin powerhouse Kimberly-Clark is acquiring Kenvue for $48.7 billion, adding brands like Tylenol and Listerine. The deal is expected to deliver $1.9–2.1 billion in cost synergies and $500 million in profit from revenue synergies within a few years. This expands KMB's portfolio and boosts long-term earnings power.

    The Kenvue deal is the biggest strategic move and directly affects KMB's future growth and profitability.

  • Defensive business and dividend appeal Kimberly-Clark's recession-resistant brands like Huggies and Kleenex provide steady demand. The stock offers a 4.7% dividend yield and has raised dividends for 54 straight years. It trades at about 14 times earnings, below its historical average, making it attractive to income and value investors.

    This explains why investors are willing to pay up for KMB despite market volatility.

  • Arbex joint venture sharpens focus on higher-margin products Kimberly-Clark formed a joint venture called Arbex with Suzano, offloading its lower-margin paper-towel and tissue business. This frees up resources to integrate Kenvue and focus on higher-margin personal-care products, potentially improving overall profitability.

    This strategic move supports margin expansion and the Kenvue integration.

  • Integration and cost risks could weigh on results The Kenvue deal brings execution and integration risks. Also, a California distribution center fire and Middle East conflict inflation are expected to cut second-quarter revenue by $20 million and earnings by $50 million. If oil averages $100 per barrel, additional input costs of $150–170 million could hit the second half.

    These are real near-term headwinds that could pressure KMB's stock if they worsen.

© 2026 MarketIVWhy